Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis.

IF 4.5 2区医学 Q1 ONCOLOGY

Cancers Pub Date : 2024-10-21 DOI:10.3390/cancers16203551

Neil D Almeida, Cathleen Kuo, Tyler V Schrand, Julia Rupp, Venkatesh S Madhugiri, Victor Goulenko, Rohil Shekher, Chirag Shah, Dheerendra Prasad

{"title":"Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis.","authors":"Neil D Almeida, Cathleen Kuo, Tyler V Schrand, Julia Rupp, Venkatesh S Madhugiri, Victor Goulenko, Rohil Shekher, Chirag Shah, Dheerendra Prasad","doi":"10.3390/cancers16203551","DOIUrl":null,"url":null,"abstract":"Background/objectives: To determine the impact of stereotactic radiosurgery on outcomes of metastatic breast cancer with intracranial metastases.Methods: We systematically searched the PubMed and EMBASE databases for studies published between 1 January 1990 and 1 August 2024. Primary research articles evaluating the outcomes of stereotactic radiosurgery on intracranial metastases from breast cancer were included. Adverse events were defined as leptomeningeal disease, radiation necrosis, seizure, and headache. The pooled estimate was calculated using the DerSimonian and Laird approach.Results: Sixteen studies encompassing 1228 patients met the inclusion criteria. Our analysis revealed a median survival duration of 13.1 ± 3.8 months and a pooled 1-year overall survival rate of 53.1% after SRS treatment. There was a 29% local recurrence rate at 1 year and a 35% overall distant recurrence rate. In addition, our analysis found a relatively low rate of acute adverse events at 15.5%.Conclusions: SRS demonstrates promising efficacy and safety in managing intracranial metastases from breast cancer, with a favorable toxicity profile.","PeriodicalId":9681,"journal":{"name":"Cancers","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11506708/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/cancers16203551","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: To determine the impact of stereotactic radiosurgery on outcomes of metastatic breast cancer with intracranial metastases.

Methods: We systematically searched the PubMed and EMBASE databases for studies published between 1 January 1990 and 1 August 2024. Primary research articles evaluating the outcomes of stereotactic radiosurgery on intracranial metastases from breast cancer were included. Adverse events were defined as leptomeningeal disease, radiation necrosis, seizure, and headache. The pooled estimate was calculated using the DerSimonian and Laird approach.

Results: Sixteen studies encompassing 1228 patients met the inclusion criteria. Our analysis revealed a median survival duration of 13.1 ± 3.8 months and a pooled 1-year overall survival rate of 53.1% after SRS treatment. There was a 29% local recurrence rate at 1 year and a 35% overall distant recurrence rate. In addition, our analysis found a relatively low rate of acute adverse events at 15.5%.

Conclusions: SRS demonstrates promising efficacy and safety in managing intracranial metastases from breast cancer, with a favorable toxicity profile.

查看原文本刊更多论文

立体定向放射外科治疗颅内乳腺转移瘤：系统回顾与元分析》。

背景/目的确定立体定向放射手术对颅内转移的转移性乳腺癌治疗效果的影响：我们在 PubMed 和 EMBASE 数据库中系统检索了 1990 年 1 月 1 日至 2024 年 8 月 1 日期间发表的研究。纳入了评估立体定向放射外科治疗乳腺癌颅内转移效果的主要研究文章。不良事件定义为脑膜外疾病、放射性坏死、癫痫发作和头痛。采用 DerSimonian 和 Laird 方法计算汇总估计值：16项研究共纳入1228名患者，符合纳入标准。我们的分析显示，SRS 治疗后的中位生存期为（13.1 ± 3.8）个月，汇总的 1 年总生存率为 53.1%。1年的局部复发率为29%，总体远处复发率为35%。此外，我们的分析还发现急性不良反应发生率相对较低，仅为15.5%：SRS在治疗乳腺癌颅内转移方面具有良好的疗效和安全性，而且毒性反应良好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancers Medicine-Oncology

CiteScore

8.00

自引率

9.60%

发文量

5371

审稿时长

18.07 days

期刊介绍： Cancers (ISSN 2072-6694) is an international, peer-reviewed open access journal on oncology. It publishes reviews, regular research papers and short communications. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced.